^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
05/24/2022
Excerpt:
REVLIMID is a thalidomide analogue indicated for the treatment of adult patients with...Previously treated follicular lymphoma (FL), in combination with a rituximab product...
Evidence Level:
Sensitive: A1 - Approval
Published date:
06/14/2007
Excerpt:
Revlimid in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Published date:
11/26/2020
Excerpt:
In relapsed FL, lenalidomide plus rituximab may be considered for patients with short remissions after ChT [II, B]….In later relapses, a non-ChT approach is recommended [III, C]: lenalidomide plus rituximab [II, B]…
DOI:
10.1016/j.annonc.2020.11.008
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Follicular Lymphoma: First-line therapy…Preferred regimens…Lenalidomide + rituximab
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

INTERIM ANALYSIS OF MAGNIFY PHASE IIIB: INDUCTION R2 FOLLOWED BY MAINTENANCE IN RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN LYMPHOMA (INHL).

Published date:
11/26/2020
Excerpt:
…in pts with R/R FL gr1-3a, MZL…lenalidomide 20 mg/d, d1-21/28 + rituximab 375 mg/m2/wk c1 and then q8wk c3+ (R2) are given...ORR was 69% with 40% CR/CRu. Median DOR was 39.0 mo, and median PFS was 40.1 mo…
DOI:
10.1016/j.htct.2020.10.372
Trial ID: